title: Current and potential therapeutic targets of glucagon-like peptide-2.
abstract: Glucagon-like peptide-2 (GLP-2) is a gut hormone that promotes highly specific growth and function of the intestinal epithelium. Recent studies have begun to elucidate the complex mechanism of action of GLP-2, which is mediated indirectly through other intestinal factors. Although a long-acting GLP-2 analog has recently been approved for treatment of adult patients with short bowel syndrome, there remain numerous conditions characterized by intestinal insufficiency for which pre-clinical studies, as well as some limited clinical data, support further consideration of GLP-2 for expanded therapeutic use.
authors: Department of Physiology, Rm 3366 Medical Sciences Building, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada.
authors: Kaori
authors: K
authors: Austin
authors: Department of Physiology, Rm 3366 Medical Sciences Building, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada.
authors: Melanie A
authors: MA
authors: Markovic
authors: Department of Physiology, Rm 3366 Medical Sciences Building, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada; Department of Medicine, Rm 3366 Medical Sciences Building, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada. Electronic address: p.brubaker@utoronto.ca.
authors: Patricia L
authors: PL
authors: Brubaker
mesh_terms: D000328:Adult; D000818:Animals; D003692:Delayed-Action Preparations; D053767:Glucagon-Like Peptide 2 / Q000008:administration & dosage* / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007410:Intestinal Diseases / Q000188:drug therapy* / Q000473:pathology; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000473:pathology; D012778:Short Bowel Syndrome / Q000188:drug therapy* / Q000473:pathology
chemical_list: D003692:Delayed-Action Preparations; D053767:Glucagon-Like Peptide 2